Cover Image
Market Research Report

Anti-CD20 Monoclonal Antibodies (mABs) Market by Product and Geography - Global Forecast and Analysis 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 907856
Published Content info 133 Pages
Delivery time: 1-2 business days
Price
Back to Top
Anti-CD20 Monoclonal Antibodies (mABs) Market by Product and Geography - Global Forecast and Analysis 2019-2023
Published: August 21, 2019 Content info: 133 Pages
Description

About this market

Technavio's anti-CD20 monoclonal antibodies (mABs) market analysis considers sales from oncology, neurology, and immunology. Our analysis also considers the sales of anti-CD20 monoclonal antibodies (mABs) in Asia, Europe, North America, and ROW. In 2018, the oncology segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing awareness of cancer treatment through anti-CD20 mABs will help the oncology segment to maintain its market position. Also, our global anti-CD20 monoclonal antibodies (mABs) market report looks at factors such as increased use of combination therapies, high target affinity, and specificity of anti-CD20 mABs, and strong pipeline and recent approvals. However, adverse effects of anti-CD20 mABs, the introduction of rituximab biosimilars, and the emergence of alternative therapies may hamper the growth of the anti-CD20 monoclonal antibodies (mABs) industry over the forecast period.

Overview

High target affinity and specificity of anti-CD20 mABs

Anti-CD20 mABs are proven highly effective as target therapies in treating CD20-related indications. These antibodies attack CD20 antigen on cancer cells, unlike conventional therapies. The growing R&D in this space and positive results of clinical trials for late-stage molecules will support the growth prospects of the global anti-CD20 monoclonal antibodies (mABs) market, leading it at a CAGR of over 9% during the forecast period.

Development of CD20 bispecific antibodies

The bispecific antibodies are a combination of two or more antigens into a single product and can bind two or more specific targets, more than one pathway at the target disease. The blocking of the several biological pathways allows bispecific antibodies to display a synergistic effect, which is unachievable with a mixture of monospecific antibodies. This helps in optimizing expenses by reducing the cost of drug development and clinical trials. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global anti-CD20 monoclonal antibodies (mABs) market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global anti-CD20 monoclonal antibodies (mABs) market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading anti-CD20 monoclonal antibodies (mABs) manufacturers, that include Amgen Inc., Celltrion Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc.

Also, the anti-CD20 monoclonal antibodies (mABs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR31859

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Oncology - Market size and forecast 2018-2023
  • Neurology - Market size and forecast 2018-2023
  • Immunology - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing awareness about therapeutic areas
  • Presence of reimbursement and patient assistance programs
  • Development of CD20 bispecific antibodies

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Celltrion Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Oncology - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Approved mABs for cancer indications
  • Exhibit 22: Oncology - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Neurology - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Neurology - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Immunology - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Immunology - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Some of the approved anti-CD20 mABs in US
  • Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in North America
  • Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Some of the approved anti-CD20 mABs in Europe
  • Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Europe
  • Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in Asia
  • Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Top 3 countries in ROW
  • Exhibit 45: Key leading countries
  • Exhibit 46: Market opportunity
  • Exhibit 47: Some of the major combination therapies for anti-CD20 mABs
  • Exhibit 48: Serious side effects of anti-CD20 mABs
  • Exhibit 49: Effect on RITUXAN sales after the launch of biosimilars
  • Exhibit 50: Some of the recently approved rituximab biosimilars
  • Exhibit 51: Impact of drivers and challenges
  • Exhibit 52: Some of the CD20 bispecific antibodies under development
  • Exhibit 53: Vendor landscape
  • Exhibit 54: Landscape disruption
  • Exhibit 55: Vendors covered
  • Exhibit 56: Vendor classification
  • Exhibit 57: Market positioning of vendors
  • Exhibit 58: Amgen Inc. - Vendor overview
  • Exhibit 59: Amgen Inc. - Organizational developments
  • Exhibit 60: Amgen Inc. - Geographic focus
  • Exhibit 61: Amgen Inc. - Key offerings
  • Exhibit 62: Amgen Inc. - Key customers
  • Exhibit 63: Celltrion Inc. - Vendor overview
  • Exhibit 64: Celltrion Inc. - Product segments
  • Exhibit 65: Celltrion Inc. - Organizational developments
  • Exhibit 66: Celltrion Inc. - Geographic focus
  • Exhibit 67: Celltrion Inc. - Segment focus
  • Exhibit 68: Celltrion Inc. - Key offerings
  • Exhibit 69: Celltrion Inc. - Key customers
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 73: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 74: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 77: Novartis AG - Vendor overview
  • Exhibit 78: Novartis AG - Business segments
  • Exhibit 79: Novartis AG - Organizational developments
  • Exhibit 80: Novartis AG - Geographic focus
  • Exhibit 81: Novartis AG - Segment focus
  • Exhibit 82: Novartis AG - Key offerings
  • Exhibit 83: Novartis AG - Key customers
  • Exhibit 84: Pfizer Inc. - Vendor overview
  • Exhibit 85: Pfizer Inc. - Business segments
  • Exhibit 86: Pfizer Inc. - Organizational developments
  • Exhibit 87: Pfizer Inc. - Geographic focus
  • Exhibit 88: Pfizer Inc. - Segment focus
  • Exhibit 89: Pfizer Inc. - Key offerings
  • Exhibit 90: Pfizer Inc. - Key customers
  • Exhibit 91: Validation techniques employed for market sizing
  • Exhibit 92: Definition of market positioning of vendors
Back to Top